/

Ayala Pharmaceuticals, Inc.

ADXS US

ADXS USAyala Pharmaceuticals, Inc.

United States Composite

1.19

USD

+0.04

(+3.48%)

Next Earnings

March 25

Dividend Date

March 29

Held by Insiders

0.02%

Held by Institutions

16.65%

Short % of Float

0.54%

YTD Yield

3.48%

3Y Yield

-97.10%

5Y Yield

-99.58%

Capital Structure

FRC

•

in mil. unless spec.

ST Debt

LT Borrowings

LT Finance Leases

Preferred Equity and Hybrid Capital

Shares Outstanding

Market Capitalization

Working Capital

FRC

•

in mil. unless spec.

Total Current Assets

Cash, Cash Equivalents & STI

Accounts Receivable, Net

Inventories

Total Current Liabilities

Payables & Accruals

ST Debt

Deferred Revenue

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years

5 years

1 year

Sales/Revenue/Turnover

- -

Net Income, GAAP

- -

Free Cash Flow

- -

Total Cash Common Dividend

- -

Total Equity

- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

-Infinity

- -

-Infinity

- -

-Infinity

- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

-Infinity

- -

-Infinity

- -

-Infinity

- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

-Infinity

- -

-Infinity

- -

-Infinity

- -

Company Description

Sector: Healthcare
Industry: Biotechnology
Address: 1007 North Orange Street Wilmington DE United States 19802
CIK: 0001100397
Website: www.ayalapharma.com
Business: Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.

Company Description

Sector: Healthcare
Industry: Biotechnology
Address: 1007 North Orange Street Wilmington DE United States 19802
CIK: 0001100397
Website: www.ayalapharma.com
Business: Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.